The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy (HRT) is not suitable. Fezolinetant (also called Veoza and made by Astellas ...
The National Institute for Health and Care Excellence

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...
National Institute for Health and Care Excellence

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS

This means the medicines should not be provided on the NHS as they are not good value for money. Last month the appraisal committee met to consider new information submitted as part of its additional ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 TA878 29 March 2023 26 February 2026 ...
National Institute for Health and Care Excellence

Intrapartum care

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...
National Institute for Health and Care Excellence

Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

COVID-19 rapid guideline: critical care in adults

This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
National Institute for Health and Care Excellence

Indoor air quality at home

This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.
National Institute for Health and Care Excellence

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

We have moved interventional procedures guidance 615 to become HealthTech guidance 472. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...